Acumen Pharmaceuticals (ABOS) Enterprise Value (2021 - 2026)

Acumen Pharmaceuticals has disclosed Enterprise Value across 6 years of filings, most recently posting $82.9 million for Q2 2026.

• In Q2 2026, Enterprise Value rose 213.38% year-over-year to $82.9 million; the TTM figure through Jun 2026 stood at $82.9 million (up 213.38% YoY), while the FY2025 annual figure was $10.9 million, up 116.06% from the prior year.
• Enterprise Value came in at $82.9 million for Q2 2026 at Acumen Pharmaceuticals, up from $42.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $206.1 million in Q3 2022 to a low of -$115.1 million in Q2 2024.
• Average Enterprise Value over 5 years is $854038.0, with a median of -$4.4 million recorded in 2022.
• Year-over-year, Enterprise Value surged 11688.93% in 2023 and sank 798.01% in 2025.
• Over 5 years, Enterprise Value stood at $43.9 million in 2022, then sank by 148.13% to -$21.1 million in 2023, then slumped by 222.5% to -$68.2 million in 2024, then soared by 116.06% to $10.9 million in 2025, then surged by 656.99% to $82.9 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $82.9 million in Q2 2026, $42.1 million in Q1 2026, and $10.9 million in Q4 2025.